DE68924979T2 - Nachweis der expression von neu genen und produkten. - Google Patents

Nachweis der expression von neu genen und produkten.

Info

Publication number
DE68924979T2
DE68924979T2 DE68924979T DE68924979T DE68924979T2 DE 68924979 T2 DE68924979 T2 DE 68924979T2 DE 68924979 T DE68924979 T DE 68924979T DE 68924979 T DE68924979 T DE 68924979T DE 68924979 T2 DE68924979 T2 DE 68924979T2
Authority
DE
Germany
Prior art keywords
oncogenes
neu
expression
products
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68924979T
Other languages
English (en)
Other versions
DE68924979D1 (de
Inventor
A Weinberg
P Mazzara
H Morgan
J Mckenzie
J Marks
Walter P Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Oncogene Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogene Science Inc filed Critical Oncogene Science Inc
Application granted granted Critical
Publication of DE68924979D1 publication Critical patent/DE68924979D1/de
Publication of DE68924979T2 publication Critical patent/DE68924979T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE68924979T 1988-04-18 1989-04-18 Nachweis der expression von neu genen und produkten. Expired - Lifetime DE68924979T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18250188A 1988-04-18 1988-04-18
US29718889A 1989-01-13 1989-01-13
PCT/US1989/001636 WO1989010412A1 (en) 1988-04-18 1989-04-18 Detection of neu gene expression and products

Publications (2)

Publication Number Publication Date
DE68924979D1 DE68924979D1 (de) 1996-01-11
DE68924979T2 true DE68924979T2 (de) 1996-10-24

Family

ID=26878143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924979T Expired - Lifetime DE68924979T2 (de) 1988-04-18 1989-04-18 Nachweis der expression von neu genen und produkten.

Country Status (8)

Country Link
EP (1) EP0412116B1 (de)
JP (3) JPH03505964A (de)
KR (1) KR900700625A (de)
AT (1) ATE130873T1 (de)
AU (1) AU3568289A (de)
CA (1) CA1341191C (de)
DE (1) DE68924979T2 (de)
WO (1) WO1989010412A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
WO1991005264A1 (en) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993021319A1 (en) * 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU4645293A (en) * 1992-06-26 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The The met proto-oncogene and a method for predicting breast cancer progression
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6709858B1 (en) * 1997-11-03 2004-03-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US7098191B2 (en) 1997-11-03 2006-08-29 The Arizona Board Of Reagents Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
NZ522444A (en) 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AU2003212415A1 (en) 2002-03-01 2003-09-16 Bayer Corporation Assays to monitor levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) in cancer patients
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
EP2399605A1 (de) 2005-02-23 2011-12-28 Genentech, Inc. Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CN104271761B (zh) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
IE56509B1 (en) * 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection

Also Published As

Publication number Publication date
EP0412116A1 (de) 1991-02-13
CA1341191C (en) 2001-02-27
WO1989010412A1 (en) 1989-11-02
AU3568289A (en) 1989-11-24
JP2000175692A (ja) 2000-06-27
JPH03505964A (ja) 1991-12-26
KR900700625A (ko) 1990-08-16
JP2004043486A (ja) 2004-02-12
DE68924979D1 (de) 1996-01-11
ATE130873T1 (de) 1995-12-15
EP0412116B1 (de) 1995-11-29

Similar Documents

Publication Publication Date Title
DE68924979T2 (de) Nachweis der expression von neu genen und produkten.
WO1987007646A3 (en) Detection of point mutations in neu genes
Rachkovsky et al. Melanoma× macrophage hybrids with enhanced metastatic potential
Jones et al. In vitro correlates of transformation in C3H/10T½ clone 8 mouse cells
ES8802257A1 (es) Un metodo para detectar cuantitativamente una secuencia seleccionada de oligo-o-poli-desoxinucleotido en una muestra.
ATE92538T1 (de) Verstaerkung und nachweis von nukleinsaeuresequenzen.
ES8609473A1 (es) Un metodo para detectar material genetico objetivo
DE69528653T2 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
FI875082A (fi) Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner.
DE69940969D1 (de) Detektion von neoplasien durch speichelanalyse
Kolodner et al. Gene 4 protein of bacteriophage T7. Purification physical properties, and stimulation of T7 DNA polymerase during the elongation of polynucleotide chains.
DE69120936D1 (de) Genetischer test für zytochrom-p450
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
DE68923665D1 (de) Nachweis von Campylobacter.
CN105525010A (zh) 一种茎环结构组合探针及其应用
EP0128018A3 (en) Molecular genetic probe, and method of forming same, assay technique and kit using said molecular genetic probe
Widdowson et al. The relationship between M-antigen and opacity factor in group A streptococci
DE68926658T2 (de) Diagnostische gene zum nachweis von toxoplasmose
Nash Purification of Bacteriophage λ, Int Protein
DE69940770D1 (de) Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom
ATE309389T1 (de) Verfahren zum entdecken von telomerase-aktivität
ATE293707T1 (de) Nukelinsäure primer und proben zum nachweis von tumorzellen
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
Ohno et al. Antigenic relatedness of the DNA polymerase of human breast cancer particles to the enzyme of the Mason-Pfizer monkey virus.
Viola et al. Differences in murine leukaemia virus-specific DNA sequences in normal and malignant cells

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ONCOGENE SCIENCE, INC., UNIONDALE, N.Y., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: OSI PHARMACEUTICALS,INC.(N.D.GES.D.STAATES DELAWAR